iRhythm Technologies (NASDAQ:IRTC) Given New $200.00 Price Target at Robert W. Baird

iRhythm Technologies (NASDAQ:IRTC) had its target price cut by Robert W. Baird from $220.00 to $200.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other research firms have also recently weighed in on IRTC. BTIG Research raised their price target on iRhythm Technologies from $195.00 to $215.00 and gave the company a “buy” rating in a report on Friday, October 31st. Needham & Company LLC reissued a “buy” rating and issued a $244.00 target price on shares of iRhythm Technologies in a report on Monday, January 12th. Citigroup boosted their price target on shares of iRhythm Technologies from $205.00 to $242.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Wells Fargo & Company increased their price objective on shares of iRhythm Technologies from $220.00 to $225.00 and gave the company an “overweight” rating in a research report on Tuesday, January 13th. Finally, Truist Financial set a $200.00 target price on shares of iRhythm Technologies in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, iRhythm Technologies presently has an average rating of “Moderate Buy” and an average price target of $211.62.

iRhythm Technologies Stock Performance

IRTC opened at $150.96 on Friday. The company has a debt-to-equity ratio of 5.32, a quick ratio of 4.50 and a current ratio of 4.63. The stock has a market capitalization of $4.86 billion, a price-to-earnings ratio of -107.83 and a beta of 1.06. The company has a fifty day moving average of $164.65 and a 200 day moving average of $171.29. iRhythm Technologies has a fifty-two week low of $92.52 and a fifty-two week high of $212.00.

iRhythm Technologies (NASDAQ:IRTC) last released its quarterly earnings data on Thursday, February 19th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.02 by $0.27. iRhythm Technologies had a negative net margin of 5.96% and a negative return on equity of 31.44%. The business had revenue of $208.89 million during the quarter, compared to the consensus estimate of $202.61 million. During the same quarter in the prior year, the firm earned ($0.04) EPS. The business’s revenue was up 27.1% on a year-over-year basis. As a group, sell-side analysts forecast that iRhythm Technologies will post -1.98 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Chad Patterson sold 280 shares of the stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $184.83, for a total value of $51,752.40. Following the sale, the insider owned 43,387 shares of the company’s stock, valued at approximately $8,019,219.21. This represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Patrick Michael Murphy sold 2,478 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total transaction of $458,008.74. Following the completion of the sale, the insider owned 53,281 shares of the company’s stock, valued at $9,847,927.23. This trade represents a 4.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Root Financial Partners LLC bought a new stake in shares of iRhythm Technologies during the 3rd quarter worth approximately $30,000. Measured Wealth Private Client Group LLC purchased a new stake in iRhythm Technologies in the third quarter worth $30,000. GAMMA Investing LLC lifted its position in shares of iRhythm Technologies by 48.4% during the fourth quarter. GAMMA Investing LLC now owns 184 shares of the company’s stock worth $33,000 after purchasing an additional 60 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of iRhythm Technologies by 100.0% during the third quarter. Smartleaf Asset Management LLC now owns 198 shares of the company’s stock valued at $34,000 after purchasing an additional 99 shares during the period. Finally, FNY Investment Advisers LLC purchased a new stake in shares of iRhythm Technologies during the third quarter valued at $34,000.

Trending Headlines about iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q4 results beat estimates — Revenue $208.9M (+27.1% YoY) and EPS $0.29 topped consensus; management reported record quarterly revenue, improved gross margin and positive GAAP net income for the quarter. Globe Newswire: Q4 Results
• Positive Sentiment: Beating the street — Third‑party coverage highlights the earnings and revenue beat and improved profitability metrics (adjusted EBITDA, cash flow). These operational improvements support upside case over time. Zacks: Earnings Beat
• Neutral Sentiment: Company materials available — Earnings call transcript and slide deck published for investors to evaluate management commentary and forward drivers (AC C presentations and upcoming data cadence). Useful for confirming guidance/assumptions. Seeking Alpha: Call Transcript
• Neutral Sentiment: Market coverage noted positive market reaction after the print in some outlets — short-term sentiment can swing quickly as investors parse details. MassDevice: Market Reaction
• Negative Sentiment: Analysts trimmed price targets across several firms today (Canaccord, JPMorgan, Wells Fargo, Robert W. Baird) — ratings remain generally positive/overweight but lower targets reduce near‑term upside expectations and can pressure the stock. Benzinga: Analyst Target Changes
• Negative Sentiment: Insider selling and institutional rebalancing highlighted — multiple insider sales and large shifts in fund holdings raise concern about near-term selling pressure and supply overhang. Quiver: Insider & Institutional Activity

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.